The Priority Review

Clinical trials

Aumseqa, Baxfendy, and Boehringer Ingelheim: the issue of November 9, 2026

The week of November 9 to 15, 2026: 60 briefs, 15 stories, led by Aumseqa, Baxfendy, and Boehringer Ingelheim.

Compiled by code from the week's stream briefs and stories linked below; no model wrote this page. How we use automation

In this story: Contents

The week of November 9 to 15, 2026 on The Priority Review: 60 briefs and 15 stories, led by Aumseqa, Baxfendy, and Boehringer Ingelheim. Every line links its page.

Stories this week

Terms this week

  • Temporary Floor for Small Biotech Drugs – a limit that stops CMS from offering or accepting a counteroffer for an MFP below a set floor on certain qualifying Small Biotech Drugs, for initial price applicability years 2029 and 2030. (CMS: Medicare Drug Price Negotiation Program final rule fact sheet)
  • Progression-free survival – the time from randomization to the first occurrence of progressive disease or death from any cause, whichever occurred first, as the record defines it for this study. (NCT04294810 study record)
  • ACR50 – a measure that requires at least a 50% improvement in the number of tender joints and swollen joints, plus at least a 50% improvement in three of the five other core disease activity measures, as Lilly's release defines it. (Lilly release)
  • Overall Survival – the time from randomization to death from any cause, as the record defines this primary outcome. Participants still alive at the clinical cut-off date were censored at the last date known to be alive. (NCT07226752 study record)
  • Wilson disease – A rare inherited disorder that prevents the body from getting rid of extra copper. (MedlinePlus: Wilson Disease)
  • Project Orbis – A framework for concurrent submission and review of oncology products, started by the FDA's Oncology Center of Excellence in May 2019 to coordinate cancer drug reviews with international regulatory partners. (FDA: Project Orbis)
  • Epworth Sleepiness Scale – A questionnaire with 8 items asking how likely a person was to fall asleep over the past week. Higher total scores mean more severe daytime sleepiness. (study record: NCT05458128)
  • Primary membranous nephropathy – A rare kidney disease caused by an immune system attack on the glomeruli, the tiny filters that clean waste products from the blood. The damaged filters leak large amounts of protein into the urine. (FDA: FDA Approves First Drug to Treat Adults with Primary Membranous Nephropathy)
  • Project Orbis – An initiative of the FDA Oncology Center of Excellence. It provides a framework for concurrent submission and review of oncology drugs among international partners. (FDA: FDA approves durvalumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer)
  • first-in-human study – A clinical trial in which a new drug, procedure or treatment is tested in humans for the first time, usually as a phase I trial after laboratory and animal testing. (Cancer.gov dictionary: first-in-human study)
  • eligibility criteria – In clinical trials, requirements that must be met for a person to be included in a trial. (Cancer.gov dictionary: eligibility criteria)
  • clinical trial sponsor – A person, company, institution, group, or organization that oversees or pays for a clinical trial and collects and analyzes the data. (Cancer.gov dictionary: clinical trial sponsor)

Approvals briefs

  • FDA approves first drug to treat adults with primary membranous nephropathy. The FDA approved Gazyva (obinutuzumab) injection for adults with primary membranous nephropathy at risk of disease progression to induce remission of proteinuria. In the MAJESTY Phase 3 study, 36% of patients achieved complete remission at week 104 versus 6% with tacrolimus. Source: FDA approval page, November 13, 2026.
  • FDA approves durvalumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer. On November 13, 2026, the FDA approved durvalumab (Imfinzi, AstraZeneca) in combination with enfortumab vedotin-ejfv as neoadjuvant treatment followed by single-agent durvalumab as adjuvant therapy after radical cystectomy for adult patients with muscle invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy. The approval was granted under priority review and six weeks ahead of the FDA goal date. Source: FDA approval page, November 13, 2026.
  • CHMP adopts positive opinion on Aumseqa. The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a marketing authorization for Aumseqa, a 55 mg film-coated tablet intended for first-line treatment of adult patients with advanced NSCLC harbouring EGFR exon 19 deletions or L858R mutations, and for treatment of EGFR T790M mutation-positive NSCLC. The applicant for the medicinal product is SFL Pharmaceuticals Deutschland GmbH. Source: Source record, November 13, 2026.
  • CHMP adopts positive opinion on Baxfendy. The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on 12 November 2026, recommending marketing authorization for Baxfendy, a baxdrostat tablet for uncontrolled hypertension. The opinion was issued by the EMA for AstraZeneca AB. Source: Source record, November 13, 2026.
  • CHMP adopts positive opinion on Donrafylix. On 12 November 2026 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for Donrafylix, a biosimilar insulin aspart intended for the treatment of diabetes mellitus. The applicant is Kuraci BV and Donrafylix will be available as a 100 units/ml solution for injection. Source: Source record, November 13, 2026.
  • CHMP adopts positive opinion on Fondaparinux sodium Evumed. On 12 November 2026 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a marketing authorization for Fondaparinux sodium Evumed, a generic of Arixtra. The product is intended for prevention of venous thromboembolic events in adults undergoing major orthopaedic or abdominal surgery, immobilised patients, and for treatment of unstable angina, myocardial infarction, superficial-vein thrombosis, deep-vein thrombosis and pulmonary embolism. Source: Source record, November 13, 2026.

7 more briefs in Approvals.

Clinical trials briefs

29 more briefs in Clinical trials.

Regulation briefs

Policy briefs

  • Olympus announces CMS valuation and reimbursement rates for new ESD CPT codes. Olympus said the U.S. Centers for Medicare & Medicaid Services published final valuations and CY2027 Medicare reimbursement rates for two new Category I CPT codes, CPT 43498 for upper gastrointestinal ESD and CPT 45991 for lower gastrointestinal ESD, effective Jan. 1, 2027. The company noted the rates reflect the clinical complexity and physician work involved in ESD. Source: Source record, November 12, 2026.
  • PAI pharma acquires nexus pharmaceuticals expanding sterile injectable portfolio. PAI pharma announced the acquisition of nexus pharmaceuticals, adding an established commercial portfolio of over 20 hospital injectable products. The deal builds on PAI's investment in domestic sterile manufacturing and expands its hospital-focused pharmaceutical portfolio. Source: Source record, November 12, 2026.
  • Amyris to acquire sweet protein innovator Oobli. Amyris, Inc. announced it will acquire Oobli, a leading sweet protein innovator, to add a proven protein technology platform to its biomanufacturing capabilities. The acquisition is expected to close in the coming weeks, with all existing customer commitments and brand partnerships honored uninterrupted. Source: Source record, November 12, 2026.
  • Cold Spring Harbor Laboratory hosts 21st Double Helix Medals dinner. The 21st annual Double Helix Medals dinner raised $6.5 million for CSHL's biological research and education programs. The event honored Dr. Kevin J. Tracey and philanthropist Michael Milken. Source: Source record, November 12, 2026.
  • Zinzino acquires Uzesta to boost distribution capabilities in the APAC region. Zinzino has acquired the rights to Uzesta Global LLC's distributor database, inventory and intellectual property rights through subsidiaries in Taiwan, Hong Kong and Thailand. The deal includes a fixed purchase price of 0.8 mUSD in cash and a deferred price of 0.4 mUSD, with potential additional payments up to 6.0 mUSD based on future sales. Source: Source record, November 11, 2026.
  • IMVIONIX acquires U.S. and Canadian rights to BEOVU. IMVIONIX Inc. announced it has acquired exclusive commercial rights to BEOVU (brolucizumab-dbll) in the United States and Canada from Novartis, marking the company's official commercial launch. BEOVU is FDA-approved for treating neovascular (wet) age-related macular degeneration and diabetic macular edema. Source: Source record, November 10, 2026.

2 more briefs in Policy.

How this issue is made

Code builds this page every Monday from the week's published briefs and stories, listed above. The three topics in the title are the names the briefs tag most often that week. No model writes this page.